drugset / Trial / NCT07569081

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT07569081

Phase 2/3 Not yet recruiting 136 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.

Timeline

Start
2026-08-05
Primary completion
2028-12-06
Completion
2031-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Momelotinib Small molecule
Background Prednisolone Other / unclassified
Background Prednisone Other / unclassified

Indications